ACTION ALERT: Please urge Your Senators to Sign Letter to FDA – Applying FDASIA Tools to Duchenne

Earlier this year, 109 members of the House of Representatives sent a powerful letter to the FDA urging them to “utilize all available tools, resources, and authorities” in reviewing a treatment for Duchenne muscular dystrophy. Congressional champions Congressmen Mike Fitzpatrick (R-PA), Bill Keating (D-MA), and Peter King (R-NY) led this incredible bipartisan letter. It was because of YOU and your advocacy that we were able to get 109 signatures!

We are now ready to turn to the Senate!

In an effort to make the message from Congress bicameral (both House and Senate) with one unified voice, our long-standing champions in the Senate, Senator Roger Wicker (R-MS) and Senator Amy Klobuchar (D-MN) are leading a similar Senate letter urging the FDA to utilize all available resources and authorities to accelerate the process of getting safe and effective treatments to Duchenne patients. Senator Elizabeth Warren (D-MA) has already signed on as an original co-signer!

With only a few weeks left before Sarepta’s Advisory Committee Meeting with the FDA and in anticipation of future Ad Comms and FDA product reviews, we need everyone to reach out to your two Senators today and urge them to sign this important letter, to help ensure that the FDA is using all available tools during the review process.

  • The clinical and research community have accelerated therapy development to the point of FDA review.
  • Our families have spent years participating in the natural history studies and clinical trials needed to generate evidence of these products safety and efficacy profiles.
  • Congress has ensured that regulators have the resources and authorities to review these products through legislation called FDASIA. (Food and Drug Safety and Innovation Act passed in 2012, which included regulatory flexibility tools for rare disease.)

Please urge your Senators to join this effort by signing this
important letter. Patients need and deserve therapeutic options and the FDA must use the tools they have been given to expedite these options.

Views: 1974


You need to be a member of PPMD Community to add comments!

Join PPMD Community

Need help using this community site? Visit Ning's Help Page.



© 2021   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service